Global ADC (Antibody Drug Conjugates) Linker and Conjugation Market Analysis Report 2023-2035: Addressing Safety and Efficiency - The Crucial Role in Drug Development
DUBLIN, Oct. 18, 2023 /PRNewswire/ -- The "ADC Technology Market: Focus on ADC Linker and ADC Conjugation Technologies (2nd Edition) - Distribution by Generation of ADC Technology, Type of Conjugation, Type of Linker and Key Geographical Regions: Industry Trends and Global Forecasts, 2023-2035" report has been added to ResearchAndMarkets.com's offering.
The ADC technology market, comprising of ADC linker and antibody conjugation technologies is expected to grow at compounded annual growth rate (CAGR) of ~15% during 2023-2035
The market report presents an extensive analysis of the current market landscape, market size, and future prospects within the ADC linker and antibody conjugation industry during the forecast period. It also sheds light on the initiatives undertaken by various stakeholders involved in this rapidly emerging sector of the pharmaceutical industry. Below, we provide a brief overview of key insights from the ADC technology market.
Up to this point, approximately 14 ADCs have gained approval from the USFDA, with over 420 antibody drug conjugates currently undergoing evaluation at various developmental stages. Antibody drug conjugates represent a complex and adaptable class of biotherapeutics, wherein linker moieties are attached to cytotoxic payloads. However, the intricate structure and design of antibody drug conjugates present significant challenges concerning overall tolerability and effectiveness.
Consequently, the demand for advanced and more effective antibody drug conjugate technology has risen to facilitate the controlled assembly of these conjugates while preserving tolerability and safety profiles. Antibody/ADC conjugation technologies typically encompass the modification or engineering of antibodies for conjugation with payload/linker-drug moieties.
In contrast, ADC linker technologies focus on developing structural elements to securely link payloads with antibodies, ensuring desired payload delivery mechanisms. These technologies are fine-tuned to produce homogenous antibody drug conjugates with a high drug-to-antibody ratio (DAR). ADCs developed through these technologies have demonstrated enhanced stability and efficacy within tumor microenvironments.
Homogenous ADCs created using optimized linker technologies offer the advantage of reduced immunogenicity, enabling precise delivery of linker-payload complexes to target sites without adverse effects. This has prompted the entry of numerous startups and established industry players into the ADC linker and conjugation technology sector. They offer innovative conjugation/bioconjugation technologies, more potent payloads, and advanced linker chemistries.
Many of these entities have forged licensing agreements to advance their ADC development initiatives. It is noteworthy that researchers and developers of antibody drug conjugates actively collaborate with ADC linker and conjugation technology firms possessing technical expertise and market experience.
Fueled by the increasing demand for antibody drug conjugates, the ADC linker and conjugation technologies market is poised for substantial growth throughout the forecast period.
Rising Interest in ADC Linker and Antibody Conjugation Technology for the Development of Homogenous Antibody Drug Conjugate
In 2000, the USFDA approved the first ADC, Mylotarg. However, it was withdrawn voluntarily from the market due to safety concerns and poor clinical benefits of the product. With continued research in the area of ADCs, innovators have identified various factors that determine the success of an antibody drug conjugate; these include structure and design of an antibody drug conjugate, systemic toxicity, validation of tumor biomarkers, choice of antibody and potency of the payload.
The challenges associated with conventional drug products have led to the development of advanced ADC linker and ADC conjugation technologies. These technologies have the potential to develop antibody drug conjugates with improved stability and toxicity profile, while maintaining efficient release of the cytotoxic payload at the desired location.
The most important characteristic of these technologies is the production of controlled, homogenous ADCs, which are site-selective and can be utilized as a targeted anti-cancer therapy.
We anticipate that the growing demand for targeted, stable and non-toxic ADCs will continue to drive the adoption and market growth of ADC linker technology and antibody conjugation technologies for development of antibody drug conjugates during the forecast period.
Current Market Landscape of ADC Technologies
The ADC technologies market landscape features an extensive list of over 65 large, mid-sized and small companies that offer more than 95 ADC linker and conjugation technologies. These platforms include linker technologies, linker-payload technologies and antibody conjugation technologies for the development of ADC.
It has been observed that the majority of the antibody drug conjugates generated via these ADC technologies are site specific, have high tolerability and precise DAR ratio. In addition, we believe that third-generation technologies are poised to play a significant role in shaping the future market landscape, by enabling the development of new therapeutic modalities that were previously considered unattainable.
The constant evolution of ADC linkers and conjugation technologies will support the development of novel and more efficacious ADCs. In turn, the growing ADC therapy market will drive the demand for these technologies, contributing to substantial CAGR of ADC technology market during the forecast period.
ADC Technology Market Size
The ADC technology market, comprising of ADC linker and antibody conjugation technologies is expected to grow at a CAGR of ~15% during the forecast period. Driven by the growing interest of stakeholders in addressing the efficiency and safety related concerns with antibody drug conjugates, the ADC linker and conjugation technologies market is anticipated to witness tremendous market growth in the foreseen future.
Based on mechanism of drug release, the linkers are categorized as cleavable or non cleavable linkers. Majority of the approved ADCs use cleavable linkers and based on the current late-stage pipeline of ADCs, the global ADC technology market is anticipated to be driven by cleavable linkers in the short term.
North America and Europe to Compete for the Largest Share of ADC Linker and Antibody Conjugation Technologies Market
Close to 80% of the market share is estimated to be captured by companies based in North America and Europe. This can be attributed to the escalating partnership activity in these regions. It is interesting to note that 78% of the total deals were inked by players based in North America and Europe during the time period, 2014-2023. Further, some of the companies based in these developed regions, such as Mersana Therapeutics, Seattle Genetics and Zymeworks offer several antibody conjugation and ADC linker technology / platforms.
These platforms are either second-generation or third-generation technologies that offer chemical site specific conjugation. Moreover, all these players have in-house ADC portfolio for testing the potential of their technologies and resulting in the development of innovative cancer therapies.
Key Topics Covered:
1. PREFACE
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Antibody-based Therapeutics
3.3 Antibody Drug Conjugates (ADCs)
3.4. Advantages of ADCs over Conventional therapeutics
3.5. ADC Linker Technologies
3.6. ADC Conjugation Technologies
3.7. Future Perspectives
4. ADC LINKER AND CONJUGATION TECHNOLOGIES: MARKET LANDSCAPE
4.1. Chapter Overview
4.2. ADC Linker and Conjugation Technologies: Overall Market Landscape
4.3. ADC Conjugation Technologies
4.4. ADC Linker and ADC Linker-Payload Technologies
4.5. ADC Linker and Conjugation Technology Providers
5. TECHNOLOGY COMPETITIVENESS ANALYSIS
5.1 Chapter Overview
5.2 Assumptions and Key Parameters
5.3 Methodology
5.4 ADC Linker and Conjugation Technologies: Technology Competitiveness Analysis
6. COMPANY PROFILES
6.1. Chapter Overview
6.2. Companies Headquartered in North America
6.2.1. Ambrx
6.2.2. Catalent Biologics
6.2.3. Mersana Therapeutics
6.2.4. Seagen
6.2.5. Sutro Biopharma
6.3. Companies Headquartered in Europe
6.3.1. Antikor Biopharma
6.3.2. Iksuda Therapeutics
6.3.3. Heidelberg Pharma
6.3.4. LinXis Biopharmaceuticals
6.3.5. NBE-Therapeutics
6.4. Companies Headquartered in Asia-Pacific and Rest of the World
6.4.1. Alteogen
6.5.2. LegoChem Biosciences
7. PATENT ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. ADC Linker and Conjugation Technologies: Patent Analysis
7.4. Patent Benchmarking Analysis
7.5. Patent Valuation
7.6. Leading Patents by Number of Citations
8. PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models
8.3. ADC Linker and Conjugation Technologies: Partnerships and Collaborations
8.4. Regional Analysis
9. BUSINESS MODEL ANALYSIS
9.1. Chapter Overview
9.2 Assumptions / Key Parameters
9.3 Scope and Methodology
9.4. ADC Linker and Conjugation Technologies: Business Models Analysis
9.5. Most Active Players: Analysis by Number of Partnerships
9.5.1. Synaffix
9.5.2. LegoChem Biosciences
9.5.3. Catalent Biologics
9.5.4. Sutro Biopharma
9.5.5. Heidelberg Pharma
9.5.6. Mersana Therapeutics
10. LIKELY PARTNERS ANALYSIS
10.1. Chapter Overview
10.2. Assumptions / Key Parameters
10.3. Scope and Methodology
11. BRAND POSITIONING ANALYSIS
11.1. Chapter Overview
11.2 Scope and Methodology
11.3. Key Parameters
11.4. Brand Positioning Matrix: ADC Conjugation Technology Providers
11.4.1. Brand Positioning Matrix: Abzena
11.4.2. Brand Positioning Matrix: Ambrx
11.4.3. Brand Positioning Matrix: Byondis
11.4.4. Brand Positioning Matrix: Creative Biolabs
11.4.5. Brand Positioning Matrix: Eisai
11.4.6. Brand Positioning Matrix: Mersana Therapeutics
11.4.7. Brand Positioning Matrix: Sorrento Therapeutics
11.4.8. Brand Positioning Matrix: Tubulis
12. ADC THERAPEUTICS: MARKET LANDSCAPE
12.1. Chapter Overview
12.2. Antibody Drug Conjugates: Therapies Pipeline
12.3. Antibody Drug Conjugate: List of Therapy Developers
13. MARKET SIZING AND OPPORTUNITY ANALYSIS
13.1. Chapter Overview
13.2. Key Assumptions
13.3. Forecast Methodology
13.4. Global ADC Linker and Conjugation Technologies Market, 2023-2035
14. EXECUTIVE INSIGHTS
14.1. Chapter Overview
14.2. Abzena
14.3. MedLink Therapeutics
14.4. Merck KGaA
14.5. Singzyme
14.6. Ajinomoto
14.7. Eucodis Bioscience
14.8. Shanghai Miracogen
14.9. NBE-Therapeutics
14.10. Synaffix
15. CONCLUDING REMARKS
16. APPENDIX 1: TABULATED DATA
17. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
For more information about this report visit https://www.researchandmarkets.com/r/pe4rmb
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716
Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
SOURCE Research and Markets
Share this article